Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nanoformed Piroxicam vs Reference in Healthy Subjects
NCT05104931Phase 1Completed
- Sponsor
- Nanoform
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of piroxicam in osteoarthritis (OA), rheumatoid arthritis (RA), pain and 1 more (3 arms), sponsored by Nanoform. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the drug Concentration at 72 hours and 1 more. Started Dec 2020; status: completed.
02
Drugs
piroxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)paininflammation
Beyond the preview
Go deeper on NCT05104931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104931.